Astragaloside II
Based on 2 publication(s) in Google Scholar
Astragaloside II is an orally active Cycloartane-type triterpene glycoside. Astragaloside II can be extracted from Astragalus membranaceus. Astragaloside II inhibits Autophagy, decreases pro-inflammatory cytokines (IL-6, IL-1β), HIF-α, p-p65, p-IκB and increases SOD. Astragaloside II regulates immunity and reduces inflammatory responses. Astragaloside II can be used in the research of diseases such as liver cancer, osteoporosis, immunosuppressive diseases, and ulcerative colitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.45%
- CAS No.: 84676-89-1
- Formule: C43H70O15
- Masse moléculaire:827.01
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Astragaloside II
More-
Cell Proliferation/Viability Assay
Activité biologique
Astragaloside II (0.1 nM-10 μM; 48-72 h) significantly promotes the cell viability of rat primary osteoblasts in a concentration-dependent manner[1].
Astragaloside II (10-30 nM; 48-96 h) significantly enhances the proliferation of primary splenocytes induced by ConA, alloantigen or anti-CD3[3].
Astragaloside II (80 μM; 48 h) sensitizes Bel-7402/FU cells to 5-fluorouracil (HY-90006)-induced cell death via suppression of autophagy[4].
Astragaloside II (1 μM; 48 h) inhibits the levels of HIF-α, p-p65 and p-IκB in Lipopolysaccharide-stimulated CCD-18Co cells, exerting an anti-inflammatory effect[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Bel-7402/FU
-
Concentration:40 μM, 80 μM, 160 μM, 320 μM, 80 μM
-
Incubation Time:48 h
-
Result:Decreased the expression of autophagy-related proteins LC3-II and Beclin-1.
-
Cell Line:CCD-18Co
-
Concentration:0.1 μM, 0.33 μM, 1 μM, 3 μM
-
Incubation Time:48 h
-
Result:Significantly decreased the viability of CCD-18Co cells at 3 μM.
Had very limited cytotoxicity at 1 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BABL/c mice (20-22 g) with DSS-induced ulcerative colitis[5]
-
Dosage:30 mg/kg (dissolved in 2% Tween 20 in PBS), 50 mg/kg (dissolved in 2% Tween 20 in PBS)
-
Administration:Oral gavage, once per day, for 10 days
-
Result:Significantly reduced the DAI score.
Markedly prevented the body weight loss, increased the colon length, decreased the levels of pro-inflammatory cytokines IL-6, TNF-α, IL-1β, NO, MPO and MDA, and increased the level of SOD in colon tissues.
Decreased the expression of inflammatory proteins HIF-α, p-p65 and p-IκB.
Chemical Information
-
CAS No. 84676-89-1
-
Appearance Solid
-
Masse moléculaire 827.01
-
Formule C43H70O15
-
Color White to off-white
-
SMILES
O[C@H]1[C@H](O)[C@@H](OC(C)=O)[C@]([H])(O[C@@H]2C(C)(C)[C@@]([C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@]4([H])[C@@]56CC[C@@]7(C)[C@@]4(C)C[C@H](O)[C@@]7([C@]8(C)O[C@H](C(O)(C)C)CC8)[H])([H])[C@]5(C6)CC2)OC1
-
Synonyms
Astrasieversianin VIII
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Mol Histol
Astragaloside II suppresses colorectal cancer progression by upregulating LGALS4 expression. [Abstract]2026 Jun 29;57(4):199. PMID: 42319491 -
Am J Transl Res
Astragaloside II alleviates the symptoms of experimental ulcerative colitis in vitro and in vivo. [Abstract]2019 Nov 15;11(11):7074-7083. PMID: 31814910
Astragaloside II purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2019 Nov 15;11(11):7074-7083. [Abstract]
AS II (Astragaloside II) attenuates oxidative stress damage in LPS-stimulated CCD-18Co cells via decreasing the production of inflammatory factors. CCD-18Co cells are treated with LPS (1 μg/mL) for 0, 12, 24 and 48 h. In addition, CCD-18Co cells are treated with 1 μM AS II and 1 μg/mL LPS for 48 h. The level of IL-6 in the culture media is measured with ELISA. The level of TNF-α in the culture media is measured with ELISA. The level of IL-β in the culture media is measured with ELISA. CCD-18Co c
Solvant et solubilité
DMSO : 100 mg/mL (120.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kong XH, et al. Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways. Int J Mol Med. 2012 Jun;29(6):1090-8. [Content Brief]
[2]. Huang C, et al. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol. 2012 Dec;64(12):1741-50. [Content Brief]
[3]. Chun-ping Wan, et al. Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity. Acta Pharmacol Sin. 2013 Apr;34(4):522-30. [Content Brief]
[4]. Wang M, et al. Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy. J Pharm Pharmacol. 2017 Jun;69(6):743-752. [Content Brief]
[5]. Qiao C, et al. Astragaloside II alleviates the symptoms of experimental ulcerative colitis in vitro and in vivo. Am J Transl Res. 2019 Nov 15;11(11):7074-7083. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2092 mL | 6.0459 mL | 12.0918 mL | 30.2294 mL |
| 5 mM | 0.2418 mL | 1.2092 mL | 2.4184 mL | 6.0459 mL | |
| 10 mM | 0.1209 mL | 0.6046 mL | 1.2092 mL | 3.0229 mL | |
| 15 mM | 0.0806 mL | 0.4031 mL | 0.8061 mL | 2.0153 mL | |
| 20 mM | 0.0605 mL | 0.3023 mL | 0.6046 mL | 1.5115 mL | |
| 25 mM | 0.0484 mL | 0.2418 mL | 0.4837 mL | 1.2092 mL | |
| 30 mM | 0.0403 mL | 0.2015 mL | 0.4031 mL | 1.0076 mL | |
| 40 mM | 0.0302 mL | 0.1511 mL | 0.3023 mL | 0.7557 mL | |
| 50 mM | 0.0242 mL | 0.1209 mL | 0.2418 mL | 0.6046 mL | |
| 60 mM | 0.0202 mL | 0.1008 mL | 0.2015 mL | 0.5038 mL | |
| 80 mM | 0.0151 mL | 0.0756 mL | 0.1511 mL | 0.3779 mL | |
| 100 mM | 0.0121 mL | 0.0605 mL | 0.1209 mL | 0.3023 mL |